Why RedHill Biopharma Shares Are Trading Higher


RedHill Biopharma Ltd. RDHL shares are trading higher after the company published data from the Phase 2 data study of RHB-107.

What happened: Redhill Biopharma announced today that its Phase 2 data study of RHB-107, an oral antiviral used to treat COVID-19 patients, met the primary endpoint of safety and tolerability.

This comes with promising efficacy results, including faster recovery from severe COVID-19 symptoms and a 100% reduction in hospitalization due to COVID-19.

“Showing both safety and efficacy signals positively positions RHB-107 as a potentially very useful treatment for COVID-19 outpatients to reduce symptom severity and prevent disease progression and hospitalization,” Medical Director Terry F. Plasse states.

Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases.

According to data from Benzinga Pro, the stock is up approximately 22%, trading at $0.17 per share at the time of publication.

Market News and Data brought to you by Benzinga APIs
Posted In: Penny StocksMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!